Results 151 to 160 of about 50,863 (305)

Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review

JEADV Clinical Practice, EarlyView.
This systematic review identifies consistent clinical patterns of alopecia areata associated with IL‐17 and IL‐23 inhibitors, most frequently involving secukinumab and ustekinumab. Disease severity varied widely, and management often required biologic discontinuation or therapeutic switching.
Isabella Kamholtz, Simonetta I. Gaumond, Joaquin J. Jimenez   +2 more
wiley   +1 more source

Epidemiology, genetics and management of psoriatic arthritis 2013: focus on developments of who develops the disease, its clinical features, and emerging treatment options

Psoriasis: Targets and Therapy, 2013
Muhammad Haroon,1 Oliver FitzGerald,1 Robert Winchester2 1Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland; 2Division of Rheumatology, Columbia University College of Physicians and Surgeons, New York, NY, USA Abstract ...
Haroon M, FitzGerald O, Winchester R
doaj  

Successful Treatment of IL‐23 Inhibitor–Refractory Nail Psoriasis With Deucravacitinib: A Case Report

JEADV Clinical Practice, EarlyView.
ABSTRACT Nail psoriasis is a prevalent chronic inflammatory disorder that affects the nail unit and is often accompanied by psoriatic skin lesions. It is also more likely to progress to psoriatic arthritis. Here, we report the case of a 57‐year‐old woman who presented with a 3‐year history of nail dystrophy, scaling erythema, and psoriatic plaques on ...
Tianmeng Yan, Xiaoyan Wu, Zhenying Zhang
wiley   +1 more source

Optimal management of dactylitis in patients with psoriatic arthritis [PDF]

, 2015
Toshiyuki YamamotoDepartment of Dermatology, Fukushima Medical University, Fukushima, JapanAbstract: Psoriatic arthritis (PsA) is an inflammatory arthropathy associated with cutaneous psoriasis, which is currently classified as a seronegative ...
Yamamoto T
core   +1 more source

The Effects of Biologic Agents on Carotid Intima‐Media Thickness and Hepatic Steatosis in Patients With Moderate‐To‐Severe Psoriasis: A Prospective Observational Cohort Study

JEADV Clinical Practice, EarlyView.
In this prospective observational cohort study, 34 patients with moderate‐to‐severe psoriasis received biologic therapy (anti‐TNF‐α, anti‐IL‐12/23, or anti‐IL‐17) for 6 months. Carotid intima–media thickness decreased significantly in the overall cohort (p < 0.01), with the greatest reductions in the anti‐IL‐17 and anti‐IL‐12/23 groups.
Harika Ödemiş, Burçe Can Kuru, Bilal Doğan, Ceyda Civan Kuş, Mehmethan Çelik, Nurhilal Kızıltoprak, Fatih Özçelik   +6 more
wiley   +1 more source

Harnessing Natural Compounds in Psoriasis: Targeting Cellular Pathways for Effective Therapy

Phytotherapy Research, EarlyView.
Natural compounds act on key cellular pathways in psoriasis by suppressing keratinocyte hyperproliferation, modulating Th17/IL‐17‐mediated immune responses, and reducing oxidative stress. These multi‐target effects highlight their potential as safer adjunctive therapies alongside conventional treatments.
Hye Jin Lee, Yu Jin So, Il‐Joo Jo, Ji Yong Jang, Tae Han Yook, Jun Ho Lee, Sung Wook Kim, Kangwook Lee, Soo Jung Park, Gabsik Yang   +9 more
wiley   +1 more source

A Serum N‐Glycan Ratio Associated With Disease Severity and Treatment Response in Psoriasis

The Journal of Dermatology, EarlyView.
ABSTRACT Psoriasis is a chronic, immune‐mediated inflammatory disease with heterogeneous manifestations. Reliable biomarkers reflecting disease severity and treatment response remain limited. Glycans—carbohydrate structures attached to proteins and lipids—play key roles in biological processes, contributing to functional specificity.
Kentarou Nishimura, Noritaka Oyama, Takumi Hasegawa, Hiroshi Kasamatsu, Takenao Chino, Takahiro Tokunaga, Kiyoshi Higashi, Koichi Saito, Keita Yamada, Minoru Hasegawa   +9 more
wiley   +1 more source

Topical Cycling and Systemic Eligibility in Patients With Psoriasis in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT Topical therapy is the typical first‐line treatment for psoriasis, with the International Psoriasis Council recommending systemic therapy for patients with body surface area > 10%, high‐impact site involvement, or topical therapy failure. A recent Japanese Delphi Consensus Study proposed a definition for topical failure that considers time on ...
Akimichi Morita, Shinichi Imafuku, Hideshi Torii, Lauren Peetluk, Siddharth Chaudhari, Hidehito Mizuma, Jing Liu   +6 more
wiley   +1 more source

Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic psoriasis treatment options have rapidly expanded in Japan, including the approval of tyrosine kinase 2 and interleukin‐36 receptor inhibitors in 2022. However, contemporary real‐world treatment patterns across plaque, erythrodermic, and generalized pustular psoriasis remain incompletely characterized.
Yayoi Tada, Yoshiko Maeda, Miyuki Hasegawa, Motonobu Sakaguchi, Takamasa Hashimoto, Teruko Narusawa, Nobuyoshi Takabayashi, Tomoko Takahashi, Taisuke Kondo, Shingo Kuroda   +9 more
wiley   +1 more source

Redefining “Comorbidity” in Dermatology: Beyond Terminology, Lessons From Other Specialties

JEADV Clinical Practice, EarlyView.
Patricia Garbayo‐Salmons, Mireia Moreno   +1 more
wiley   +1 more source